Cargando…
Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients
PURPOSE: Cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) is a treatment for post-transplant lymphoproliferative disease (PTLD) following solid organ transplant (SOT) after failing rituximab, an aggressive and potentially fatal lymphoma. This study explores the humanistic and economic b...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782278/ https://www.ncbi.nlm.nih.gov/pubmed/33489434 http://dx.doi.org/10.1080/21556660.2020.1854561 |
_version_ | 1783631864732319744 |
---|---|
author | Watson, Crystal Barlev, Arie Worrall, Jodie Duff, Steve Beckerman, Rachel |
author_facet | Watson, Crystal Barlev, Arie Worrall, Jodie Duff, Steve Beckerman, Rachel |
author_sort | Watson, Crystal |
collection | PubMed |
description | PURPOSE: Cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) is a treatment for post-transplant lymphoproliferative disease (PTLD) following solid organ transplant (SOT) after failing rituximab, an aggressive and potentially fatal lymphoma. This study explores the humanistic and economic burden of CHOP-associated adverse events (AEs) in PTLD patients. Since PTLD is rare, searches included lymphoproliferative disease with lymphoma patients. DESIGN: This comprehensive literature review used the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) protocol, pre-specifying the search strategy and criteria. CHOP-associated short-term AEs with an incidence of >4% were sourced from published literature and cancer websites to inform the search strategy. PubMed and EMBASE searches were used to identify humanistic and economic burden studies. RESULTS: PubMed and EMBASE searches identified 3946 citations with 27 lymphoma studies included. Studies were methodologically heterogeneous. Febrile neutropenia (FN) was the AE most encountered, followed by chemotherapy-induced (CI) anemia (A), infection, CI-nausea and vomiting, thrombocytopenia, and CI-peripheral neuropathy (PN). FN and infections were associated with significant disutility, increased hospitalization, and extended length of stay (LOS). Infections and CIPN significantly impacted the utility of patients and CIA-related fatigue showed reductions in quality of life (QoL). Many patients continue to have QoL deficits continued even after AEs were treated. Management costs varied greatly, ranging from nominal (CIPN) to over $100,000 in the USA for infections, EUR 10,290 in Europe for infections, or CAN$1012 in Canada for FN. Cost of outpatient care varied but had a lower economic impact compared to hospitalizations. CONCLUSIONS: Short-term AEs from CHOP in the lymphoma population were associated with substantial humanistic and economic burden. |
format | Online Article Text |
id | pubmed-7782278 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-77822782021-01-21 Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients Watson, Crystal Barlev, Arie Worrall, Jodie Duff, Steve Beckerman, Rachel J Drug Assess Immunology PURPOSE: Cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) is a treatment for post-transplant lymphoproliferative disease (PTLD) following solid organ transplant (SOT) after failing rituximab, an aggressive and potentially fatal lymphoma. This study explores the humanistic and economic burden of CHOP-associated adverse events (AEs) in PTLD patients. Since PTLD is rare, searches included lymphoproliferative disease with lymphoma patients. DESIGN: This comprehensive literature review used the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) protocol, pre-specifying the search strategy and criteria. CHOP-associated short-term AEs with an incidence of >4% were sourced from published literature and cancer websites to inform the search strategy. PubMed and EMBASE searches were used to identify humanistic and economic burden studies. RESULTS: PubMed and EMBASE searches identified 3946 citations with 27 lymphoma studies included. Studies were methodologically heterogeneous. Febrile neutropenia (FN) was the AE most encountered, followed by chemotherapy-induced (CI) anemia (A), infection, CI-nausea and vomiting, thrombocytopenia, and CI-peripheral neuropathy (PN). FN and infections were associated with significant disutility, increased hospitalization, and extended length of stay (LOS). Infections and CIPN significantly impacted the utility of patients and CIA-related fatigue showed reductions in quality of life (QoL). Many patients continue to have QoL deficits continued even after AEs were treated. Management costs varied greatly, ranging from nominal (CIPN) to over $100,000 in the USA for infections, EUR 10,290 in Europe for infections, or CAN$1012 in Canada for FN. Cost of outpatient care varied but had a lower economic impact compared to hospitalizations. CONCLUSIONS: Short-term AEs from CHOP in the lymphoma population were associated with substantial humanistic and economic burden. Taylor & Francis 2020-12-24 /pmc/articles/PMC7782278/ /pubmed/33489434 http://dx.doi.org/10.1080/21556660.2020.1854561 Text en © 2020 Atara Biotherapeutics. Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Immunology Watson, Crystal Barlev, Arie Worrall, Jodie Duff, Steve Beckerman, Rachel Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients |
title | Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients |
title_full | Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients |
title_fullStr | Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients |
title_full_unstemmed | Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients |
title_short | Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients |
title_sort | exploring the burden of short-term chop chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782278/ https://www.ncbi.nlm.nih.gov/pubmed/33489434 http://dx.doi.org/10.1080/21556660.2020.1854561 |
work_keys_str_mv | AT watsoncrystal exploringtheburdenofshorttermchopchemotherapyadverseeventsinposttransplantlymphoproliferativediseaseacomprehensiveliteraturereviewinlymphomapatients AT barlevarie exploringtheburdenofshorttermchopchemotherapyadverseeventsinposttransplantlymphoproliferativediseaseacomprehensiveliteraturereviewinlymphomapatients AT worralljodie exploringtheburdenofshorttermchopchemotherapyadverseeventsinposttransplantlymphoproliferativediseaseacomprehensiveliteraturereviewinlymphomapatients AT duffsteve exploringtheburdenofshorttermchopchemotherapyadverseeventsinposttransplantlymphoproliferativediseaseacomprehensiveliteraturereviewinlymphomapatients AT beckermanrachel exploringtheburdenofshorttermchopchemotherapyadverseeventsinposttransplantlymphoproliferativediseaseacomprehensiveliteraturereviewinlymphomapatients |